The convergence of psoriasis treatment cost-effectiveness over time: "Real world" considerations in economic modeling

Journal of the American Academy of Dermatology

Volumn 58, Issue 6, 2008, Pages 1073-1075

  Goldberg, Lawrence D ^a  

^a Goldberg MD and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; EDITORIAL; HUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT RESPONSE;

COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MODELS, ECONOMIC; PSORIASIS; TIME FACTORS;

EID: 43249111506     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.02.009     Document Type: Editorial

References (10)

1. Nelson A.A., Pearce D.J., Fleischer Jr. A.B., Balkrishnan R., and Feldman S.R. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 58 (2008) 125-135
2. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., Griffiths C.E., et al. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
3. Gordon K.B., and Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. Drugs Dermatol 2 (2003) 624-628
4. Menter A., Cather J.C., Baker D., Farber H.F., Lebwohl M., and Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
5. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
6. Gottlieb A.B., Hamilton T., Caro I., Kwon P., Compton P.G., Leonardi C.L., et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 4 Suppl 1 (2006) S154-S163
7. Tyring S., Gordon K.B., Poulin Y., Langley R.G., Gottlieb A.B., Dunn M., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
8. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) 31.e1-15
9. National Library of Medicine Website. HTA 101: Glossary. Available at: http://www.nlm.nih.gov/nichsr/hta101/ta101014.html. Accessed January 7, 2008.
10. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6 (2003) 9-17